Pivotal Response Treatment Plus NAO Robot Effective in Autism

Share this content:
Pivotal Response Treatment Plus NAO Robot Effective in Autism
Pivotal Response Treatment Plus NAO Robot Effective in Autism

THURSDAY, May 10, 2018 (HealthDay News) -- Parent-mediated pivotal response treatment (PRT) using a humanoid (NAO) robot may be effective for reducing autism spectrum disorder (ASD)-related symptoms in young children, according to a study presented at the annual meeting of the International Society for Autism Research, held from May 9 to 12 in Rotterdam, Netherlands.

Iris Smeekens, from the Radboud University Medical Center in the Netherlands, and colleagues examined the effectiveness of a NAO robot within parent-mediated PRT in young children with ASD. Seventy-four children aged 3 to 8 years with ASD were randomized to either parent-mediated PRT using the NAO robot (PRT+robot), parent-mediated PRT, or treatment as usual (TAU). Parents were trained in use of PRT techniques; the robot was added in all parent-child sessions in the PRT+robot condition.

The researchers found that in the PRT+robot condition, there was a significant main effect of time and a time × group interaction effect on the Social Responsiveness Scale completed by parents, indicating a steeper decrease in ASD-related symptoms over time. Compared with both the PRT and TAU conditions, the percentage of clinical responders on the Clinical Global Impression-Improvement Scale was significantly higher in the PRT+robot condition (66.7 versus 36.4 and 36.4 percent, respectively) at week 20, but not at follow-up.

"The use of robotics in PRT may be an effective treatment component in diminishing ASD-related symptoms and improving general clinical functioning in young children with ASD," the authors write.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »